New potential diabetes treatment targets inflammation
Researchers from Albany and NYU have developed RAGE406R, a small molecule aimed at reducing inflammation in diabetes by blocking key cellular pathways, with promising cell test results and plans for clinical trials.
Scientists from the University at Albany and NYU Grossman School of Medicine have created a potential new diabetes treatment option for patients with type 1 or type 2 diabetes, according to an announcement.
The drug, a small molecule called RAGE406R, was designed to “block a key cellular pathway known to drive chronic inflammation and impaired wound healing in people with diabetes.” The researchers hope to fill a gap in diabetes treatment, the absence of medications for this inflammation.
RAGE406R stops the “Receptor for Advanced Glycation End products” (RAGE) and “Diaphanous-1” (DIAPH1) from connecting and causing inflammation. RAGE406R proved to be successful when tested on cells from patients with type 1 diabetes. The authors hope their drug will be tested in clinical trials.
